CriticalTricyclic antidepressants (TCA)×Selective serotonin reuptake inhibitor (SSRI)
Updated · Methodology
Mechanism
Paroxetine strongly inhibits the enzyme CYP2D6, and the liver clears amitriptyline mainly through CYP2D6 and CYP2C19. Strong CYP2D6 inhibitors, paroxetine among them, markedly slow amitriptyline breakdown and sharply raise its blood levels (paroxetine and amitriptyline summaries of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). In people with inactive CYP2D6 (poor metabolisers), the area under the concentration curve (AUC) of a tricyclic antidepressant can rise up to 8-fold. Inhibitors of this enzyme make normal metabolisers resemble poor metabolisers, and a person stable on the same dose may suddenly become toxic (amitriptyline label, US Food and Drug Administration, FDA). Amitriptyline itself prolongs the QT interval: QT prolongation on the electrocardiogram is among its common adverse reactions, and QT prolongation and arrhythmias have been reported after marketing (amitriptyline SmPC, AEMPS). According to the paroxetine FDA label, higher levels of CYP2D6 substrates that prolong the corrected QT interval (QTc) may lengthen QTc further and lead to torsade de pointes, other serious arrhythmias and sudden death. Tricyclic antidepressants taken with paroxetine also raise the risk of serotonin syndrome (paroxetine FDA label). Paroxetine itself has only weak anticholinergic activity (paroxetine SmPC, AEMPS), but when another drug raised tricyclic antidepressant levels, their adverse effects, particularly anticholinergic ones, became more frequent and more severe (amitriptyline FDA label).
Symptoms
Excess amitriptyline causes anticholinergic symptoms: dilated pupils, fast heart rate, urinary retention, dry mucous membranes and slowed bowel movement. Severe cases bring seizures, fever, depressed consciousness up to coma and respiratory depression (amitriptyline summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Cardiac effects include ventricular arrhythmias such as torsade de pointes and ventricular fibrillation. The electrocardiogram (ECG) shows longer PR and QT intervals and a wider QRS complex, and blood pressure falls (amitriptyline SmPC, AEMPS). Older people are particularly sensitive to the anticholinergic effects of amitriptyline: constipation, blurred vision, confusion, psychomotor slowing, sedation, delirium and falls (amitriptyline label, US Food and Drug Administration, FDA). Serotonin syndrome causes agitation, hallucinations, confusion, fast heart rate, labile blood pressure, sweating, fever, tremor, muscle rigidity, muscle jerks, seizures, nausea, vomiting and diarrhoea (paroxetine FDA label).
Management
The combination is contraindicated. In its September 2026 version, the US Food and Drug Administration (FDA) paroxetine label contraindicates paroxetine with drugs that prolong the QT interval and are CYP2D6 substrates, and amitriptyline meets both conditions according to its own labels (paroxetine FDA label; amitriptyline summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The Spanish SmPCs are softer: use amitriptyline with caution in people taking selective serotonin reuptake inhibitors (SSRIs), and if a strong CYP2D6 inhibitor such as paroxetine is added, consider a lower amitriptyline dose and monitoring of amitriptyline blood levels (amitriptyline SmPC, AEMPS). If the patient still takes both, lower the amitriptyline dose if needed. After paroxetine is stopped, the amitriptyline dose may have to go up again (amitriptyline and paroxetine FDA labels). Take care when switching from one drug to the other (amitriptyline and paroxetine FDA labels). Watch for serotonin syndrome, especially at the start of treatment and after dose increases. If it appears, stop both drugs at once and start supportive treatment (paroxetine and amitriptyline FDA labels). Use paroxetine with caution together with drugs that prolong QT, especially with bradycardia, heart disease, low potassium or low magnesium (paroxetine SmPC, AEMPS). Potassium and magnesium disturbances also raise the risk of arrhythmia with amitriptyline (amitriptyline SmPC, AEMPS). Paroxetine together with most tricyclic antidepressants raises the risk of bleeding, so the combination calls for caution (paroxetine SmPC, AEMPS). In older people, start amitriptyline at low doses and observe them closely because of its anticholinergic effects and the risk of falls (amitriptyline FDA label).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica Frosinor 20 mg (paroxetina) (2026)– AEMPS CIMA, Frosinor 20 mg comprimidos recubiertos con película, nº registro 59466, secciones 4.3, 4.4 y 4.5
- FDA: Paxil (paroxetine) prescribing information (2026)– Apotex Corp. PAXIL (paroxetine) tablets. Prescribing information, DailyMed setid ef3b5cbe-f9e1-c1ac-79da-cfe14e3a7e7e, sections 4, 5.11 and 7
- FDA: Amitriptyline hydrochloride tablets (amitriptyline) prescribing information (2026)– FDA label, Sun Pharmaceutical Industries, DailyMed setid 4e520c63-1cf6-40f6-a51c-3f9b0e181342, revised 09/2026, Contraindications, Warnings (Serotonin Syndrome) and PRECAUTIONS: Drug Interactions (Drugs Metabolized by P450 2D6)
- AEMPS: Ficha técnica: Amitriptilina, Tryptizol 25 mg (nº registro 37130), secciones 4.4 y 4.5 (2025)– AEMPS, CIMA, nº registro 37130, revisión 01/2025, secciones 4.4 y 4.5
- AEMPS: Ficha técnica: Amitriptilina (nº registro 89862), sección 4.4 (2026)– AEMPS, CIMA, nº registro 89862 (Amitriptilina hidrocloruro Tarbis 25 mg), revisión 05/2026, secciones 4.2, 4.4 y 4.5